Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab in Active Polymyositis and Dermatomyositis
NCT03981744Phase 3Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2019
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in polymyositis (PM) and dermatomyositis (DM) comparing Ustekinumab with Placebo -> Ustekinumab (2 arms). Primary endpoint: Percentage of Participants Who Achieved Minimal Improvement in International Myositis Assessment and Clinical Studies Total Improvement Score at 24 weeks. Started Jul 2019; status: terminated.
02
Drugs
ustekinumab
03
Conditions
polymyositis (PM)dermatomyositis (DM)
Beyond the preview
Go deeper on NCT03981744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03981744.